Features

Cheshire’s hard cell: who will bid for AstraZeneca's Alderley Park site?

By 22 November 2013

Alderley-Park

AstraZeneca’s decision to leave its Alderley Park R&D facility is a bitter blow to the local economy. Four bidders could provide an antidote.

This content is only available to registered users

You must be logged in to continue

Gated access promo

Would you like to read more?

Try Property Week For Free to finish this article.

Sign up now for the following benefits:

  • Unlimited access to Property Week
  • Breaking news, comment and analysis from industry experts as it happens
  • Choose from our portfolio of email newsletters

To access this article TRY FOR FREE NOW

Don’t want full access? REGISTER NOW to read this article and up to 3 more this month and subscribe to our newsletters.

Registered users and subscribers SIGN IN here to continue